Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$133.08 USD
-0.38 (-0.28%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $133.07 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 461 - 480 ( 672 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Panic Has Created Some Compelling Opportunities on the Long Side
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen NDA Accepted, All Eyes on Advisory Committee Meetings Later this Year; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen NDA Accepted, All Eyes on Advisory Committee Meetings Later this Year; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 24
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Flibanserin Approval a Sign of Regulatory Flexibility - DMD Lives Matter
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Color on Full Sarepta Data Package Ahead of Advisory Committee Meeting this Fall
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: 2H15 Catalysts For Key Stocks From Our Research Universe
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
On A Strategic High-Ground Should Regulatory Flexibility Holdup
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Submissions Moving Ahead as Expected -- 2H15 a Key Determinant of the DMD Landscape
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H